Mission Creek Capital Partners Inc. Sells 565 Shares of Johnson & Johnson (NYSE:JNJ)

Mission Creek Capital Partners Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,243 shares of the company’s stock after selling 565 shares during the quarter. Johnson & Johnson accounts for 1.1% of Mission Creek Capital Partners Inc.’s holdings, making the stock its 24th biggest position. Mission Creek Capital Partners Inc.’s holdings in Johnson & Johnson were worth $4,577,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 37.6% in the third quarter. IHT Wealth Management LLC now owns 59,683 shares of the company’s stock worth $9,670,000 after acquiring an additional 16,297 shares in the last quarter. Intrepid Capital Management Inc. increased its stake in Johnson & Johnson by 8.9% during the 3rd quarter. Intrepid Capital Management Inc. now owns 7,118 shares of the company’s stock worth $1,154,000 after purchasing an additional 582 shares in the last quarter. Independent Family Office LLC lifted its stake in Johnson & Johnson by 24.8% in the third quarter. Independent Family Office LLC now owns 4,120 shares of the company’s stock valued at $669,000 after buying an additional 820 shares in the last quarter. Investmark Advisory Group LLC boosted its holdings in shares of Johnson & Johnson by 2.1% in the third quarter. Investmark Advisory Group LLC now owns 19,868 shares of the company’s stock valued at $3,220,000 after buying an additional 403 shares during the period. Finally, Investment Management Corp of Ontario raised its holdings in shares of Johnson & Johnson by 13.0% during the third quarter. Investment Management Corp of Ontario now owns 211,928 shares of the company’s stock worth $34,345,000 after acquiring an additional 24,305 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Citigroup upped their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Guggenheim lifted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $175.67.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $152.31 on Wednesday. The firm’s fifty day moving average price is $158.77 and its two-hundred day moving average price is $156.45. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $366.70 billion, a P/E ratio of 22.04, a P/E/G ratio of 2.75 and a beta of 0.51. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the firm earned $2.66 EPS. The business’s revenue was up 5.2% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.